Post-earnings recap
Reported
Mon, Nov 3, 2025
EPS actual
$2.43
EPS est.
$0.24
EPS surprise
+904.13%
1-day move
-3.13%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
TG Therapeutics reported a significant EPS beat, which is a positive sign for profitability. However, the stock fell by 3.13% in reaction, likely due to the absence of revenue figures and future guidance. Investors may be concerned about the lack of clarity on revenue generation moving forward.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.43 | N/A | +904.13% |
| Revenue | N/A | N/A | N/A |
Management expressed cautious optimism about the future, focusing on the significant EPS surprise. They did not provide specific revenue guidance.
Management highlighted the strong performance in EPS despite the lack of revenue guidance.
They emphasized ongoing efforts to enhance operational efficiencies.